Abiopharma

Chopas James George 🔴 sold 548 shares of Apellis Pharmaceuticals, Inc. (APLS) at $28.08 Transaction Date: Sep 02, 2025 | Filing ID: 021110

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves Disease Patients

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves Disease Patients

New Form 6-K - Sanofi Filed: 2025-09-03 AccNo: 0001193125-25-194750 Size: 41 KB

AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem

New Form 144 - CATALYST PHARMACEUTICALS, INC. Filed: 2025-09-03 AccNo: 0001959173-25-005734 Size: 4 KB

Law Offices of Frank R. Cruz Encourages LifeMD, Inc. (LFMD) Investors To Inquire About Securities Fraud Class Action

Law Offices of Frank R. Cruz Encourages Semler Scientific Inc. (SMLR) Investors To Inquire About Securities Fraud Class Action

Boucher Kelley 🟢 acquired 76.2K shares (1 derivative) of Apellis Pharmaceuticals, Inc. (APLS) at $28.17 ($1.3M) Transaction Date: Sep 02, 2025 | Filing ID: 021104

New Form 144 - Teladoc Health, Inc. Filed: 2025-09-03 AccNo: 0001959173-25-005732 Size: 5 KB

Arcutis Submits Supplemental New Drug Application forZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

SCWorx Corp. Appoints New Chief Technology Officer to Accelerate Innovation in Healthcare Data Solutions

Zentek Announces Changes to Board of Directors and Changes to Board Nominations for Upcoming Annual and Special Meeting of Shareholders

New Form 6-K - XORTX Therapeutics Inc. Filed: 2025-09-03 AccNo: 0001171843-25-005700 Size: 17 KB

Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results